Physician profile
Robert Snyder
NPI 1841256351
$14,720.59
in general payments reported to CMS, 2019-2025
79 companies · $3,562 in 2025
The $3,562 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,349 · 2020: $558 · 2021: $1,072 · 2022: $1,841 · 2023: $2,254 · 2024: $3,084 · 2025: $3,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,786 · Education: $87.49 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,786.48 |
| Education | $87.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,401.33 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $944.68 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $917.77 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $655.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $590.93 | 2019-2025 | |
| Biogen, INC. | $529.45 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Amgen INC. | $527.14 | 2019-2025 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $514.63 | 2020-2025 | Epidiolex, Xywav |
| Celgene Corporation | $503.56 | 2022-2025 | Zeposia |
| Lundbeck LLC | $490.43 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $433.80 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Tg Therapeutics, INC. | $429.55 | 2024-2025 | |
| Mdd US Operations, LLC | $422.77 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $412.14 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Genzyme Corporation | $361.36 | 2019-2023 |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.